NSW2031 - Randwick - Sydney Children's Hospital (SUSPENDED)2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)2305 - New Lambton Heights - John Hunter Children's Hospital (SUSPENDED)

QLD4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT04518644

Managed Access Program to Provide Access to Nilotinib, for Patients With Imatinib-intolerant and/or Resistant Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase or CML in Accelerated Phase (CAMN107A2411)

NCT04419649

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (KER050-MD-201)

NA2025 - Papatoetoe - Middlemore Hospital (COMPLETED)

3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (COMPLETED)

QLD4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (COMPLETED)

NCT04332822

R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (POLAR-BEAR)

NCT04293562

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (AAML1831)

QLD4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)

NCT04176198

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis (BBI-TP-3654-102)

NCT04094610

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE) (CA127-1029)

2145 - Westmead - The Children's Hospital at Westmead (COMPLETED)

NCT04065399

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation (AUGMENT-101)

NCT04064060

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (ACE-536-LTFU-001)

VIC3168 - Clayton - Monash Medical Centre (COMPLETED)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

NCT03959085

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (AALL1732)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

NCT03850574

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (TUSCANY)

NCT03666000

A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (PBCAR0191-01)

NCT03601442

Managed Access Programs for CTL019, Tisagenlecleucel (CCTL019B2003I)

NCT03590171

International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, M�nster (BFM) Study Group (IntReALL-HR-2010)

NCT03486873

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (3475-587)

2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (COMPLETED)

4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)4120 - Greenslopes - Greenslopes Private Hospital (COMPLETED)

NCT03409081

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (2215-CL-9200)

ACTRN12626001253392

An ALLG phase II, multicenter, open-label trial evaluating the efficacy and safety of ELVN-001 in patients With Chronic Myeloid Leukemia (CML). (ALLG-CML15)

ACTRN12626001243303

Phase 1b study evaluating the safety and efficacy of Dendritic cell Immune activation combined with Venetoclax and Azacitidine as frontline therapy for patients with newly diagnosed acute myeloid leukaemia unfit for intensive chemotherapy (DIVA)

ACTRN12626001110370

Not Applicable

Intranodal forceps and cryobiopsy for acquiring tissue from mediastinal lymph nodes during endobronchial ultrasound transbronchial nodal biopsy: A Randomised Controlled Study

ACTRN12626000900314

Changes for Australian Paediatric Patients In the Treatment of Acute Lymphoblastic Leukaemia (CAPITALL), A comparison study measuring the effectiveness of an alternative treatment schedule incorporating earlier blinatumomab and standard treatment.

ACTRN12626000809336

An open-label, first-in-human, dose escalation study to determine the pharmacokinetics, pharmacodynamics, tolerability and safety of BYT-1007 in patients with hematologic malignancies (BY103CS01)

ACTRN12626000704392

A Bayesian Phase II study with toxicity monitoring of elranatamab monotherapy in newly diagnosed systemic light-chain (AL) amyloidosis (ENLIGHT)

ACTRN12626000638336

A Dose finding Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ZE74-0282 in Select JAK2 V617F Mutated Hematologic Disorders (ZE74-0282-0002)

ACTRN12626000278336

Not Applicable

ALLG AMLM28-A3. A randomised study of ambulatory management compared to standard of care for fever related hospitalisation in patients with AML receiving Venetoclax and Azacitidine – a domain of Achieving Durable remissions via Adaptive Pro-survival Targeting in AML (ADAPT) (ADAPT-ID)

ACTRN12626000019303

A Double-blind, Phase I/II, Randomised Study to Compare the Efficacy of Enzomenib Versus Placebo as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation in Subjects with Acute Myeloid Leukaemia (AML). (ACT-MIM-001)

ACTRN12625001195448

A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies (PLATYPS)

ACTRN12625001031459

Place-of-care manufactured anti-BCMA chimeric antigen receptor (CAR) T-cells (ARI0002h) in patients with relapsed/refractory multiple myeloma.

ACTRN12625001003460

ALLG AMLM29 CAVIAT-R (Combining Anti-BCL2 and intensive chemotherapy in Acute Myeloid Leukaemia (AML) Trial- Randomised) : a multicentre phase III trial for newly diagnosed AML

ACTRN12625000994482

ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol. (ADAPT-A2)

ACTRN12625000965404

ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (CLL-RT2)

ACTRN12625000964415

ALLG AMLM30/EVOLVE II: Randomised study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy (EVOLVE-II)

ACTRN12625000824460

AMLM26/T9 - INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML)): A Multi-arm, Precision-based, Recursive, Platform Trial- PHI-101 (AMLM26-T9)

ACTRN12625000732482

CLL12 - An ALLG phase II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (AETHER-trial)

ACTRN12625000438459

A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1 - Talquetamab and Teclistamab (ZEPFHR-MM-Domain-1)

ACTRN12625000429459

A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol (ZEPFHR-MM)

ACTRN12625000387426

CLL11 - An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab (MOONSHOT)

ACTRN12625000056493

Microbiome and Fibre Supplementation in Chimeric Antigen Receptor T cell Therapy patients - phase I clinical trial of safety and feasibility of oral fibre supplementation in CAR T (Micro-Fibre-CAR)

ACTRN12624001468516

A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (Dara@Home)

ACTRN12624001142527

Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (nil)

ACTRN12624000963527

A randomised platform trial evaluating the role of interventions to prevent infection in patients with acquired hypogammaglobulinemia secondary to haematological malignancies - RATIONAL-PT (Stop-Ig Domain)

ACTRN12624000792527

Feasibility of prebiotic fibre supplementation during treatment for acute leukemia, a pilot randomised control trial in patients with newly diagnosed acute leukemia (IMPaCT-Leukemia)

ACTRN12624000738527

AMLM22/D4: The International AML Platform Consortium (IAPC) trial – is a randomised, 2-arm trial that will investigate the efficacy of oral Azacitidine combined with an allogeneic dendritic cell vaccine vididencel, compared with oral Azacitidine alone, in maintaining or inducing negativity for measurable residual disease (MRD) in AML patients in first complete remission (CR1) following intensive chemotherapy. (AMLM22-D4-CADENCE)

ACTRN12624000141549

AMLM26/T2- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - Ivosidenib + Venetoclax (AMLM26-T2)

ACTRN12624000082505

AMLM26/T1- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre- emptive Therapy in AML): A Multi-arm, Precision- based, Recursive, Platform Trial - Gilteritinib+ Venetoclax (AMLM26-T1--INTERCEPT)

ACTRN12624000065594

Not Applicable

ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain

ACTRN12624000027516

Romosozumab for Patients with Multiple Myeloma with Skeletal Events on Zoledronic Acid: A Pilot Study

ACTRN12624000006549

AMLM26/T3- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - LDAC + Venetoclax (AMLM26-T3-INTERCEPT)

ACTRN12623000900617

AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (ALLG)

ACTRN12622001366741

Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial

ACTRN12622001302741

MDS05/D2 - A multicentre phase Ib/II open label randomized platform design study to determine the safety and efficacy of SRA515 and ASTX727 for treatment of intermediate and high risk Myelodysplastic Syndrome (MDS). (ALLG)

ACTRN12622001232729

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (The-ANZHIT-2-study)

ACTRN12622001158752

MM25: A phase 1b/II study of the efficacy of Venetoclax, Iberdomide and Dexamethasone (IberVenD) for patients in first or second relapse of Multiple Myeloma with t(11;14) (ALLG-Viber-M-MM25)

ACTRN12622000856718

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study assessing safety and tolerability of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (ISB-1442-101)

ACTRN12622000582752

AMLM26/T4- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - SNDX5613 (AMLM26-T4)

ACTRN12622000308796

A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (VICTORY-study)

ACTRN12621001458820

Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib (CHARMM)

ACTRN12621001361897

A single arm, open-label study of efficacy and safety of the Exportin 1 inhibitor selinexor in relapsed/refractory CNS Lymphoma and in relapsed/refractory CNS Myeloma (EXCLAIM)

ACTRN12621001037897

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (IBIS-Study)

ACTRN12621000246886

AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option. (AMLM22-D3)

ACTRN12619000079145

A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The-AutoCAR19-Trial)

ACTRN12613001154796

A phase 2 trial of cyclophosphamide as prophylaxis for graft-versus-host disease after HLA-identical allogeneic donor transplantation using reduced intensity conditioning therapy (PT-CYCLO)

ACTRN12613000358741

The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.

ACTRN12611000605998

A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with untreated multiple myeloma. (The-BRIM-Trial)

ACTRN12611000364976

Pharmacokinetics and Safety of Solid Oral Posaconazole (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05615) (NIL)

ACTRN12610001031055

A Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-Azacitidine in AML

ACTRN12610000700033

This is a Phase II, Open-label, Multi-Dose Study of the Monoclonal Antibody MDX-1097 to determine the efficacy of the antibody in patients who have received prior treatment for myeloma and have kappa light chain restricted multiple myeloma with stable measurable disease.

ACTRN12610000641099

A single arm pilot study of azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia (AZA-E)

ACTRN12609000997257

Busilvex plus Fludarabine Vs Busilvex plus Cyclophosphamide prior allogeneic transplantation in Acure Myeloid Leukimia (AML) to evaluate the transplant-related mortality. (GITMO)

ACTRN12609000116224

A pilot study investigating the combination of Mozobil\xAE plus Neulasta\xAE for Hematopoietic progenitor Cell (HPC-A) Mobilization in Patients with Lymphoma or Multiple Myeloma

ACTRN12608000336381

An Open-label Phase I Study of the Safety and Efficacy of MDX-1097, an human IgG1k chimeric monoclonal antibody, in the Treatment of Previously Treated Kappa Light Chain Restricted Multiple Myeloma Patients with Stable Measurable Disease to determine the Safety, Tolerability and Maximum Tolerated Dose

ACTRN12608000129381

Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse

ACTRN12606000514505

A Phase III Randomized Study of Cloretazine (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse to Improve the Overall Remission Rate (Vion)

ACTRN12606000433505

A Three-Stage Phase I/II Dose-Escalation Study of High-Dose Melphalan with Palifermin for Patients with Multiple Myeloma to Determine a New Maximum Tolerated Dose (MTD) of Melphalan for use in Autografting (ALLG)

ACTRN12605000460606

A Phase I/II trial to evaluate the effects of allogeneic pegylated G-CSF mobilized stem cells in the treatment of haematological malignancy to inhibit the incidence of GVHD. (BMT-Neulasta)

NCT05607498

A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma (EMB07X101)

NCT05172700

Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers

NCT03557619

A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies (M16-185)

Bcl2	17%
cereblon	13%
CD20	12%
BCMA	11%
DNA methyltransferase	11%
CD38	10%
CD19	10%
BTK	9%
proteasome	7%
KMT2A	4%
BCR-ABL1	4%
menin	3%
JAK1	3%
JAK2	3%
menin-MLL1	3%
FLT3	3%
GPRC5D	3%
IL-6	2%
KIT	2%
PD-1	2%
PD-1/PD-L1	2%
FcRH5	2%
CD22	2%
ROR1	2%
CD79b	1%
CS1	1%
IDH1	1%
IDH1 R132	1%
AXL	1%
IL-2	1%
CALR	1%
LSD1	1%
PI3K delta	1%
CD7	1%
ALK	1%
mTOR	1%
mTORC1	1%
SRC	1%
PDGFRA	1%
BRAF	1%
RAF	1%
cytidine deaminase	1%
CD33	1%
CD47	1%
XPO1	1%
BRD4	1%
KAT6A	0%
HDAC6	0%
BET	0%
CD123	0%
CD70	0%
IRAK4	0%
MALT1	0%
RET	0%
TTR	0%
CD28	0%
DHFR	0%
HDAC	0%
ITK	0%
CAR-T-cell generating,CD19	0%
mTORC2	0%
MDM2	0%
ISR	0%
multikinase	0%
PRMT5	0%
YES1	0%
DPD	0%
orotate phosphoribosyltransferase	0%
STING	0%
CRAF	0%
EGFR	0%
CDC7	0%
CHK1	0%
FAK	0%
CD94	0%
FACT complex	0%
ROCK2	0%
TGF-beta	0%
AURKA	0%
AURKB	0%
Aurora	0%
PDGFR	0%
ROS1	0%
TRK	0%
LAG3	0%
PARP	0%
VEGF	0%
SOST	0%
CXCR4	0%

ARTICANZ - Beta (ver 0.91)

Search results

Haematologic malignancy

Filters